葡萄糖类1-激动剂和对奖励行为的影响:系统性审查
Sebastian Badulescu1, Aniqa Tabassum1, Gia Han Le1
1Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Physiology & behavior
|June 30, 2024
概括
类似葡萄糖1受体激动剂 (GLP-1RAs) 通过减少大脑对奖励的反应来减少食物摄入量和改变奖励行为. 这些发现表明GLP-1RAs可能治疗奖励功能障碍,肥胖和成.
科学领域:
- 神经科学是一个神经科学.
- 代谢调节 代谢调节 代谢调节
- 药理学 药理学是指药理学的学科.
背景情况:
- 像葡萄糖类1 (GLP-1) 这样的代谢信号会影响非代谢功能.
- 葡萄糖类1受体激动剂 (GLP-1RAs) 正在研究用于治疗行为障碍.
- 关于GLP-1RA对奖励系统的影响的证据需要系统审查.
研究的目的:
- 系统地审查GLP-1RA对人类奖励系统的影响的证据.
- 探索GLP-1RAs对奖励相关行为障碍的治疗潜力.
主要方法:
- 在主要数据库 (OVID,PubMed,Scopus,Google Scholar) 中按照PRISMA指南进行系统的文献搜索.
- 专注的搜索术语:"奖励行为"和"葡萄糖像1受体对抗剂".
- 仅包括人类研究;使用NIH标准进行质量评估.
主要成果:
- GLP-1RAs始终降低了能量摄入量,并调节了与奖励相关的行为.
- 这些药物减少了神经皮质激活,以回应奖励和食物线索,特别是高热量物品.
- 观察到的效应包括更低的热量摄入量和更低的饥饿程度.
结论:
- GLP-1RAs显示出治疗与食物刺激,肥胖和2型糖尿病 (T2DM) 相关的奖励功能障碍的潜力.
- 它们可以使胰岛素抵抗正常化,调节多巴胺激素信号传递,并缓解无情感.
- 观察到对血糖变化和渴望的效应表明对成障碍的可能应用.
相关概念视频
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
Regulation of Food Intake
217
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
217
Hypoglycemia and Glucagon
254
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
254
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Spare Receptors
3.5K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
3.5K


